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ABSTRACT
Background. Open transthoracic esophagectomy is the
worldwide gold standard in the treatment of resectable
esophageal cancer. Robot-assisted minimally invasive
thoraco-laparoscopic esophagectomy (RAMIE) for eso-
phageal cancer may be associated with reduced blood loss,
shorter intensive care unit (ICU) stay, and less cardiopul-
monary morbidity; however, long-term oncologic results
have not been reported to date.
Methods. Between June 2007 and September 2011, a total
of 108 patients with potentially resectable esophageal
cancer underwent RAMIE at the University Medical Cen-
tre Utrecht, with curative intent. All data were recorded
prospectively.
Results. Median duration of the surgical procedure was
381 min (range 264–636). Pulmonary complications were
most common and were observed in 36 patients (33 %).
Median ICU stay was 1 day, and median overall postop-
erative hospital stay was 16 days. In-hospital mortality was
5 %. The majority of patients (78 %) presented with T3
and T4 disease, and 68 % of patients had nodal-positive
disease (cN1–3). In 65 % of patients, neoadjuvant treat-
ment (chemotherapy 57 %, chemoradiotherapy 7 %,
radiotherapy 1 %) was administered, and in 103 (95 %)
patients, a radical resection (R0) was achieved. The median
number of lymph nodes was 26, median follow-up was
58 months, 5-year overall survival was 42 %, median
disease-free survival was 21 months, and median overall
survival was 29 months. Tumor recurrence occurred in 51
patients and was locoregional only in 6 (6 %) patients,
systemic only in 31 (30 %) patients, and combined in 14
(14 %) patients.
Conclusion. RAMIE was shown to be oncologically ef-
fective, with a high percentage of R0 radical resections and
adequate lymphadenectomy. RAMIE provided good local
control with a low percentage of local recurrence at long-
term follow up.
In 2008, an estimated 482,300 people were diagnosed
with esophageal cancer, and 406,800 patients died of the
disease worldwide.1 Radical esophagolymphadenectomy is
the cornerstone of the multimodality treatment with cura-
tive intent.2–5
Worldwide, open transthoracic esophagectomy is the
preferred surgical approach for esophageal cancer, allow-
ing en bloc resection of the tumor with the surrounding
paratracheal, subcarinal and paraesophageal lymph
nodes.6,7 However, the percentage of cardiopulmonary
complications associated with the open transthoracic ap-
proach is high (50–70 %).6
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Minimally invasive esophagectomy (MIE) was designed to
reduce surgical trauma, resulting in lower rates of morbidity
and mortality. With regard to MIE, a review of the literature
shows a substantial decrease in blood loss, postoperative
complications, and days of hospital stay, with comparable
short-term oncologic results.8–13 These results were confirmed
in a recently published randomized controlled trial where MIE
was compared with open transthoracic esophagectomy.14
However, open transthoracic esophagectomy remains the gold
standard worldwide for the treatment of esophageal cancer.7
In 2003, robot-assisted minimally invasive thoraco-la-
paroscopic esophagectomy (RAMIE) was developed at the
University Medical Center Utrecht (UMC Utrecht),
Utrecht, The Netherlands.15 Robot-assisted thoraco-la-
paroscopic esophagectomy facilitates complex minimally
invasive procedures with an enlarged, three-dimensional
(3D) field of view. The articulated instruments facilitate
dissection with seven degrees of freedom.13,15–18
From our first experience, reported in 2006 and 2009, it
was concluded that RAMIE is a feasible and safe tech-
nique, associated with reduced blood loss, shorter intensive
care unit (ICU) stay, and a lower percentage of car-
diopulmonary complications compared with literature
reports of open transthoracic esophagectomy.6,15,16
Following these initial reports of RAMIE, the current




Between June 2007 and September 2011, consecutive
patients with potentially curative resectable esophageal
cancer were operated on in the UMC Utrecht. In our in-
stitute, transthoracic esophagectomy is the standard
treatment for patients with esophageal cancer. The standard
neoadjuvant treatment for patients with esophageal ade-
nocarcinoma was preoperative chemotherapy [epirubicin,
cisplatin and capecitabine (ECC)].19 Patients with eso-
phageal squamous cell carcinoma underwent preoperative
chemoradiotherapy (carboplatin and taxol ? 41.4 Gy).20
Data on surgical procedures were registered prospectively
in the operating room. All complications and follow-up
were registered in a prospective surgical database.
We prospectively recorded baseline characteristics and
routine diagnostic work-up, including use and results of upper
endoscopy, endoscopic ultrasound, computed tomography
(CT) of the thorax and abdomen, and ultrasound of the neck
region. Positron emission tomography (PET) scanning with
fine-needle aspiration of the suspected lymph nodes was used
at indication and recorded prospectively. All patients were
discussed at a multidisciplinary oncology board meeting.
Patients received standard postoperative follow-up at the
outpatient department. Patients visited the outpatient de-
partment at 6 weeks and 3, 6, 9, and 12 months in the first
year, and in the second, third, fourth, and fifth year post-
operatively. Patients received follow-up every 6 months. In
case symptoms of tumor recurrence occurred, patients
underwent a CT of the thorax and abdomen. All patients
had at least 29 months of follow-up and were followed for
5 years postoperatively.
Operative Procedure
The operative technique of thoraco-laparoscopic esophagec-
tomy with two-field lymphadenectomy has been previ-
ously described.15,16 For the thoracic phase, the patient is
positioned in the left lateral decubitus position, and tilted
45 towards the prone position. The trocar arrangement
during the robot-assisted thoracoscopic and laparoscopic
phases is shown in electronic supplementary Fig. S1.15
Robot-assisted esophagectomy included a thoracic lym-
phadenectomy, which included the right-sided paratracheal
(lymph node station 2R), tracheobronchial (station 4), aor-
topulmonary window (lymph nodes in the window dorsal to
the aortic arch, cranially to the left main bronchus up until the
pulmonary artery, station 5), carinal (station 7), and perioe-
sophageal (station 8) lymph nodes.15
The patient was placed in the supine position thereafter
to facilitate a laparoscopic gastric mobilization, truncal
lymph node dissection, and gastric tube formation with
cervical hand-sewn end-to-side esophagogastrostomy.21
Postoperative Management
Mechanical ventilation was continued until patients
were transferred to the ICU, where they were extubated 2–
3 h after ending the operation. After day 1, patients were
transferred to the medium care unit (MCU) and then to the
surgical ward on postoperative day 2.
All patients were placed on a nil-by-mouth routine with
enteral tube feeding by a needle-catheter jejunostomy on the
first 7 days postoperatively. Nasogastric tubes were routinely
placed. No postoperative swallow tests were performed as the
sensitivity rate of detecting leakage was considered to be too
low to change postoperative decision making.22 In the ab-
sence of signs of anastomotic dehiscence, patients started with
sips of water and the oral intake was gradually increased to
solid food. There was no enhanced recovery program.
Postoperative Complications
All complications were graded using the modified Cla-
vien–Dindo classification (MCDC) of surgical complications.
All reported complications were grade 2 and higher.23
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Pathological Analysis
The resected specimen was evaluated using a standard
protocol, with emphasis on resection margins, tumor type,
extension of the tumor, and the presence of lymph nodes.
The 7th edition of the Union for International Cancer
Control (UICC) was used for TNM classification, tumor
grade, and stage grouping.24 The (circumferential) resec-
tion margins were evaluated using the College of American
Pathologists (CAP) criteria.25
Statistical Analysis
Statistical analysis was performed using SPSS version
20.0 (IBM Corporation, Armonk, NY, USA). A p value
of\0.05 was considered to be statistically significant. All
skewed continuous data were presented as medians and
ranges. Survival time was calculated as the duration from the
day of surgery to the date of death or date of last follow-up.
Disease-free interval was calculated from the day of surgery
to the day of definitive diagnosis of recurrent tumor.
RESULTS
Between June 2007 and September 2011, a total of 123
consecutive patients with potentially curative resectable
esophageal cancer were eligible for transthoracic esophagec-
tomy. In seven patients with locally advanced T4 tumors,
an indication for open transthoracic esophagectomy was
made preoperatively. Intraoperatively, irresectable disease
was observed in 8 patients, leaving 108 patients eligible for
RAMIE.
The baseline characteristics of patients are summarized
in electronic supplementary Table S1. The patients in-
cluded 76 men and 32 women, with a median age of
62 years (range 42–78) and a body mass index (BMI) of 26
(range 16–36 kg/m2 ). The majority of patients (78 %)
were clinically staged as cT3 and higher, and 68 % of
patients had clinically positive nodal disease (cN1–N3).
Co-morbidity, consisting of a history of vascular, cardiac,
pulmonary, and oncologic disease, was observed frequently
within this cohort.
In 20 patients (19 %), conversion to an open transtho-
racic or open transhiatal procedure was needed. Conversion
to thoracotomy (n = 11) was necessary due to bulky ad-
hesive tumor in the mediastinum (n = 4), insufficient
collapse of the right lung (n = 2), or inadequate thoraco-
scopic trocar position (n = 1). Four patients had bleeding
that could not be controlled thoracoscopically (n = 4). One
patient had bleeding from the bronchial artery, two patients
had bleeding from the azygos vein, and one patient had an
iatrogenic lung bleed. Conversion to a transhiatal proce-
dure (n = 9) was necessary due to insufficient collapse of
the right lung (n = 6), inadequate thoracoscopic port po-
sition (n = 1), pleural adhesions (n = 1), or enlarged right
cardiac atrium (unusual anatomy) (n = 1).
Conversion of the laparoscopic abdominal phase to la-
parotomy was required in three patients due to bleeding
that could not be controlled laparoscopically (n = 1), lo-
cally advanced tumor requiring total gastrectomy with
colonic interposition (n = 1), or very low position of the
greater curvature (n = 1). Patients who underwent intra-
operative conversion did not statistically differ in baseline
characteristics from patients who underwent a full RAMIE.
There was a significant decrease in the percentage of
conversions between the first group of 54 patients and the
second group of 54 patients (13 [24 %] vs. 7 [13 %], re-
spectively; p\ 0.001).
Operative Results
The operative data of 108 patients are shown in Table 1.
The median duration of the total procedure was 381 min
(range 264–550), and the thoracoscopic phase (88 patients)
had a median duration of 175 min (range 108–241). There
was a significant decrease in thoracoscopic operative time
between the first group of 44 patients and the second group
of 44 patients who completed the thoracic phase thoraco-
scopically (199 min vs. 166 min, respectively; p\ 0.001).
Postoperative Results
Postoperative data are summarized in Table 2. An un-
complicated postoperative course was observed in 37
(34 %) patients, and pulmonary complications were most
TABLE 1 Patient operative data (n = 108)
Total operating room time [min; median (range)] 381 (264–636)
Thoracoscopic phase [median (range)] 175 (108–281)
Total blood loss [ml; median (range)] 340 (50–3800)
Conversion thoracoscopy 20 (19)
Reason for conversion
Respiratory problems 8 (7)
Bleeding 4 (4)
Bulky tumor 4 (4)
Trocar problems 2 (2)
Pleural adhesions 1 (1)
Unusual anatomy 1 (1)
Conversion laparoscopy 3 (3)
Reason for conversion
Advanced tumor 1 (1)
Bleeding 1 (1)
Unusual anatomy 1 (1)
Data are expressed as n (%) unless otherwise specified
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common. Pneumonia was diagnosed and treated in 36 (33 %)
patients, and anastomotic leakage of the esophagogastros-
tomy was seen in 20 (19 %) patients, of whom 6 (6 %) also
had intrathoracic manifestation. Chylothorax was seen in
19 (18 %) patients; in 15 of these patients the leakages
were low-volume and could be treated conservatively,
showing that the leakage was only from small side
branches of the thoracic duct.
Vocal-cord paralysis occurred in ten (9 %) patients, and
paralysis was temporary in eight of these ten patients. The
permanent recurrence paralysis rate was 2 %. Wound in-
fections were seen in seven (6 %) patients; five patients were
diagnosed with a cervical wound infection, of whom one
patient also had a thoracic wound infection. The remaining
two patients had abdominal wound infections. Postoperative
pneumothorax requiring additional chest tube placement
was seen in six (6 %) patients, and thromboembolic com-
plications were seen in 6 % of patients.
Patients were ventilated at the ICU for a median of 0 days
(range 0–64). Median ICU stay was 1 day (range 1–76) and
overall postoperative hospital stay was 16 days (range 9–
123). In-hospital mortality was 5 % (four patients). One
patient died from a myocardial infarction, one from a tra-
cheo–neo-esophageal fistula, one from anastomotic leakage
with respiratory insufficiency, and one from a mediastinal
septic bleed following anastomotic leakage.
Histopathological Results
An overview of the histopathological results is shown in
Table 3. The majority of tumors were adenocarcinomas
(78 %). In ten (9 %) patients, no viable tumor cells were
detected in the resected specimen, corresponding to a
pathological complete response (pCR) rate to neoadjuvant
therapy of 14 %. The majority of tumors were located in
the distal esophagus or at the gastroesophageal junction
(GEJ) (85 %). In 102 (94 %) patients a radical resection
(R0) was achieved. No gross irradical resections (R2 re-
sections) were performed. In 108 operations, 2794 lymph
nodes were retrieved, and the median number of lymph
nodes was 26 (range 5–53). In total, 264 positive lymph
nodes were dissected, with a median of one positive lymph
node (range 0–22). The distribution of dissected lymph
nodes is shown in electronic supplementary Fig. S2. In
total, 15 % of all patients had lymph node metastases lo-
cated at the subcarinal level and higher.
Recurrence and Outcome
At the time of analysis, a median of 58 months after
surgery, all patients had undergone esophagectomy at least
TABLE 2 Postoperative data (n = 108)





Anastomotic leakage 20 (19)
Intrathoracic manifestations 6 (6)
Chylothorax 19 (18)
Vocal cord paralysisa 10 (9)
Cardiac 10 (9)
Atrial fibrillation 9 (8)
Myocardial infarction 1 (1)
Wound infection 7 (6)
Thromboembolic event 6 (6)
Pneumothorax 6 (6)
Otherb 3 (3)
In-hospital death 5 (5)
ICU stay [days; median (range)] 1 (1–76)
Hospital stay [days; median (range)] 16 (9–123)
Data are expressed as n (%) unless otherwise specified
ICU intensive care unit
a 8 temporary, 2 permanent
b 1 omentum necrosis, 1 tracheoesophageal fistula, 1 bleeding
TABLE 3 Histopathological data (n = 108)
Histological type
Adenocarcinoma 78 (72)
Squamous cell carcinoma 20 (19)
No viable tumor cells 10 (9)
Site of tumor
Mid or upper esophageal 16 (15)




No. of retrieved LNs [median (range)] 2794 [26 (5–57)]
No. of positive LNs [median (range)] 264 [1 (0–22)]











Data are expressed as n (%) unless otherwise specified
GEJ gastroesophageal junction, LNs lymph nodes
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29 months previously. No patients were lost to follow-up,
and median overall survival was 29 months. Kaplan–Meier
curves for overall survival are shown in Fig. 1. Overall 5-
year survival was 42 %.
Of 108 patients, 5 died postoperatively; therefore, 103
patients were included in the recurrence analysis. Median
disease-free survival was 21 months. In 42 patients (52 %),
no signs of recurrent disease were observed after a median
follow-up of 34 months. The remaining 39 patients de-
veloped symptomatic recurrent disease. In 52 of 103
patients (51 %), no signs of recurrent disease were ob-
served after a median follow-up of 34 months. The
remaining 51 patients developed symptomatic recurrent
disease. The first site of symptomatic tumor recurrence was
locoregional only in 6 (6 %) patients, systemic only in 31
(30 %) patients, and combined in 14 (14 %) patients
(electronic supplementary Table S2). Kaplan–Meier curves
for disease-free survival are shown in Fig. 2.
DISCUSSION
This article presents our experience with RAMIE, using
a new cohort, following our initial reports in 2006 and 2009
which showed this technique to be feasible and safe.15,16 In
the current group of consecutive patients we focused on
oncologic long-term follow-up. RAMIE was shown to be
effective, with a high percentage of R0 radical resections
(95 %) and adequate lymphadenectomy. RAMIE provided
local control, with a low percentage of local recurrence.
The high percentage of radical resections in our cohort with
a majority of locally advanced T3 tumors (60 %) may be
the result of the robotic surgical approach. Mainly, the 3D,
magnified surgical view combined with the high degree of
freedom of the articulating surgical instruments, facilitates
precise dissection in a confined operating space.18
Nodal-positive disease (pN?) was observed in 56 % of
all patients. A proper mediastinal lymphadenectomy was
performed, including the right-sided paratracheal (lymph
node station 2R), tracheobronchial (station 4), aortopul-
monary window (station 5), carinal (station 7), and
perioesophageal (station 8) lymph nodes, with a median of
26 dissected lymph nodes. This number is comparable to a
series of open transthoracic esophagectomies from the lit-
erature.6 For conventional MIE, the median number of
dissected lymph nodes was 21. Overall survival of patients
who underwent RAMIE was comparable to the results
following MIE.26,27
For recurrence, in this study the results following RAMIE
with 65 % neoadjuvant treatment were comparable with the
results reported for open esophagectomy, in which all pa-
tients received neoadjuvant chemoradiotherapy.28 The first
site of symptomatic tumor recurrence was locoregional, or in
the locoregional lymph nodes, in only 6 % of all cases. This
is comparable with results after chemoradiotherapy, where
locoregional recurrence was observed in 7 % of all cases.28
Distant metastases were observed in 30 % of all patients
compared with 28 % for patients who underwent neoadju-
vant chemoradiotherapy.28 The percentage of patients who












































FIG. 2 Kaplan–Meier curves for disease-free survival (months)
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metastases was 14 % in our cohort and 13 % after neoad-
juvant chemoradiotherapy.28
Pneumonia was the most observed complication fol-
lowing RAMIE (34 % of patients). We compared our
results with a recent randomized controlled trial where
patients with resectable esophageal cancer were random-
ized between neoadjuvant chemoradiation and surgery
alone. In this trial, only open esophagectomies were in-
cluded, showing a pneumonia rate of 44 %.20 Another
recent randomized controlled trial compared conventional
MIE with open transthoracic esophagectomy.14 Results
from this trial showed a reduced pulmonary complication
rate in the MIE group compared with the open group.14 The
percentage of in-hospital pulmonary infections after MIE
in that trial was lower (12 %) than in our study;14 however,
different definitions of postoperative pneumonia were used.
Our definition of pneumonia was defined as the decision to
treat suspected pneumonia (MCDC, grade II),23 while the
definition of pneumonia used in the randomized controlled
trial was more strict (infiltrate on pulmonary radiography
combined with a positive sputum culture), leading to a
lower percentage of pneumonia. Applying this definition to
our cohort yields a pneumonia rate of 18 %, which is
comparable to MIE.14 Reporting of postoperative pneu-
monia and postoperative outcomes after esophagectomy in
general are heterogeneous and inconsistent. This makes
comparison between different studies difficult and a con-
sensus approach to reporting clinical outcomes should be
considered.29,30
In addition to the aforementioned advantages of
RAMIE, there were also disadvantages of RAMIE, such as
the high costs of acquisition of the Da Vinci surgical sys-
tem, disposable instruments, and a prolonged operative
time compared with open esophagectomy.18 The intro-
duction of RAMIE in a hospital needs careful proctoring by
surgeons skilled and trained in RAMIE to reduce postop-
erative complications and to facilitate a steep learning
curve.15 Centralization of robotic surgery in high-volume
centers leads to a lower rate of postoperative complications
and more efficient use of operating time.31
In this article we describe a decrease in thoracoscopic
operative time between the first group of 43 patients and
the second group of 42 patients (199 min vs. 166 min,
respectively; p\ 0.001), emphasizing the learning curve.
The median duration of the full procedure is 381 min. We
are currently performing the RAMIE procedure within 6 h.
Furthermore, a significant decrease in the percentage of
conversions was observed between the first group of 54
patients and the second group of 54 patients (13 [24 %] vs.
7 [13 %], respectively; p\ 0.001). Currently our RAMIE
conversion RATE is 4 %.
Our results from robot-assisted esophagectomy are in
concordance with a recently published systematic review,18
which included nine articles (130 cases) describing robot-
assisted esophagectomy. The level of evidence for RAMIE
was suboptimal and was based on case series or expert
opinions only (level 4 or 5).18 The aforementioned sys-
tematic review strongly emphasized the need for well-
conducted randomized controlled trials and long-term
survival studies within a framework of measured and
comparable outcomes to prove the superiority of RAMIE
over the worldwide current standard of open transthoracic
esophagectomy.18 Therefore, we initiated the ROBOT trial
(ClinicalTrial.gov identifier: NCT01544790) in January
2012 to compare RAMIE with open transthoracic
esophagectomy.32
CONCLUSIONS
In a cohort of Western European patients with advanced
esophageal cancer, RAMIE with two-field lymphadenec-
tomy was shown to be feasible and safe. Furthermore,
RAMIE was shown to be oncologically effective, with a
high percentage of R0 radical resections with adequate
lymphadenectomy. RAMIE provided adequate local con-
trol, with a low percentage of local recurrence.
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